ライフサイエンスコーパス: medical therapy

1 in cases of aneurysms that do not respond to medical therapy.

2 ing and standardized, blinded, target-driven medical therapy.

3 ms despite treatment with guideline-directed medical therapy.

4 nvariably fatal despite optimal surgical and medical therapy.

5 be considered early in subjects resistant to medical therapy.

6 ssociated with outcomes with either PTRAS or medical therapy.

7 ients when compared with patients on maximal medical therapy.

8 induced hypoglycemia that is unresponsive to medical therapy.

9 isease and mortality despite advancements in medical therapy.

10 was consulted for 23 patients and started on medical therapy.

11 ause of secondary hypertension refractory to medical therapy.

12 yopathy despite receiving guideline-directed medical therapy.

13 sion models to compare device closure versus medical therapy.

14 en there is a choice between PCI and optimal medical therapy.

15 r-defibrillator and those randomized only to medical therapy.

16 surgical lung volume reduction compared with medical therapy.

17 levated heart rate despite otherwise maximal medical therapy.

18 e severely limiting and cannot be managed by medical therapy.

19 function in patients on contemporary optimal medical therapy.

20 ulatory advanced HF cohort remained alive on medical therapy.

21 ation to patients who underwent conventional medical therapy.

22 d has decreased markedly with more intensive medical therapy.

23 used in those patients who are resistant to medical therapy.

24 urgical success with the use of supplemental medical therapy.

25 vanced UC treated with elective colectomy or medical therapy.

26 s (AS) is a life-threatening disease with no medical therapy.

27 clinical trials when compared with continued medical therapy.

28 tion have refractory angina despite standard medical therapy.

29 of revascularization relative to aggressive medical therapy.

30 ized to SLT and 50 patients (99 eyes) to PGA medical therapy.

31 arterectomy in addition to ongoing intensive medical therapy.

32 at the time of occlusion and with intensive medical therapy.

33 on </=35% and CAD were randomized to CABG or medical therapy.

34 te prediction of treatment response to guide medical therapy.

35 claudication can be treated by exercise and medical therapy.

36 l transplantation may be more effective than medical therapy.

37 g cessation and exercise, as well as optimal medical therapy.

38 ate revascularization and all others receive medical therapy.

39 ained quiescent by 12 months under intensive medical therapy.

40 k patients who are non-responsive to optimal medical therapy.

41 yperresponsiveness despite receiving maximal medical therapy.

42 ce daily]) in addition to guideline-directed medical therapy.

43 iple sclerosis tremor refractory to previous medical therapy.

44 d severe symptoms, which are unresponsive to medical therapy.

45 rization and 1010 patients were treated with medical therapy.

46 and 40 subjects (55 eyes) were randomized to medical therapy.

47 igation of more aggressive interventional or medical therapies.

48 y benefit from closer follow-up and targeted medical therapies.

49 king behavior are critical to optimize acute medical therapies.

50 afety or threatens interruption of essential medical therapies.

51 who do not respond or lose responsiveness to medical therapies.

52 groups, and inclusion of patients receiving medical therapies.

53 adult IBD patients associated with available medical therapies.

54 "big data," phenomenology, and personalized medical therapies.

55 pectively (hazard ratio with PFO closure vs. medical therapy, 0.55; 95% confidence interval [CI], 0.3

56 al-therapy group (hazard ratio with CABG vs. medical therapy, 0.84; 95% confidence interval [CI], 0.7

57 vents either on (n=38) or off (n=16) optimal medical therapy, 13 (24%) had at least 1 recurrence: 0 p

58 th improved survival compared with long-term medical therapy (adjusted hazard ratio [HR], 0.67 [95% C

59 Medical therapy after revascularization targets risk fac

60 y targeted manipulation of ROS for effective medical therapies against cancer or immunological disord

61 Among patients assigned to medical therapy, all-cause mortality was similar in pati

62 oglobin level than did patients who received medical therapy alone (2.1% vs. 0.3%, P=0.003).

63 of the PFO (PFO closure group) or to receive medical therapy alone (aspirin, warfarin, clopidogrel, o

64 aire stent retriever (thrombectomy group) or medical therapy alone (control group).

65 than 5% (hazard ratio, 2.89; P = 0.009), and medical therapy alone (hazard ratio, 2.36; P = 0.018).

66 to an initial management strategy of optimal medical therapy alone (medical-therapy group) or optimal

67 y (surgery group, 57 patients) or to receive medical therapy alone (medical-therapy group, 59 patient

68 edical therapy (CABG group, 610 patients) or medical therapy alone (medical-therapy group, 602 patien

69 improvement in angina than those assigned to medical therapy alone (odds ratio: 0.70; 95% CI: 0.55 to

70 an SUVmax of less than 37.8 (P = 0.043), and medical therapy alone (P = 0.015) were also confirmed at

71 ar thrombectomy + medical therapy [n = 634]; medical therapy alone [n = 653]) enrolled in the 5 trial

72 inclusion criteria: 53 (56%) recovered with medical therapy alone and 41 (44%) underwent surgical dr

73 quality of life than did those who continued medical therapy alone at 12 months.

74 e renal artery stent procedure compared with medical therapy alone based on stenosis severity, level

75 ower rate of recurrent ischemic strokes than medical therapy alone during extended follow-up.

76 amen ovale (PFO) plus medical therapy versus medical therapy alone for cryptogenic stroke is uncertai

77 relative benefits and harms of PTRAS versus medical therapy alone for patients with ARAS is low.

78 e benefit of percutaneous closure to that of medical therapy alone for the secondary prevention of em

79 ry stent placement plus medical therapy with medical therapy alone have not shown any benefit of sten

80 ioplasty with stent placement (PTRAS) versus medical therapy alone in adults with ARAS.

81 al therapy was more effective than intensive medical therapy alone in decreasing, or in some cases re

82 predictors of early revascularization versus medical therapy alone in patients with non-ST-segment-el

83 ial strategy of PCI plus medical therapy and medical therapy alone in patients with stable ischemic h

84 were randomly assigned to receive intensive medical therapy alone or intensive medical therapy plus

85 thrombectomy + medical therapy compared with medical therapy alone was associated with lower degrees

86 as met by 2 of 38 patients (5%) who received medical therapy alone, as compared with 14 of 49 patient

87 o prompt revascularization, as compared with medical therapy alone, did not result in a significant r

88 e-directed medical therapy, as compared with medical therapy alone, in patients with coronary artery

89 core, rendering them safe for treatment with medical therapy alone.

90 edical therapy than among those who received medical therapy alone.

91 does improve angina to a greater extent than medical therapy alone.

92 -en-Y gastric bypass plus medical therapy or medical therapy alone.

93 rovascular thrombectomy with Solitaire FR or medical therapy alone.

94 ed when complications cannot be managed with medical therapy alone.

95 re assessed by FFR and who were treated with medical therapy alone.

96 l interventions and in 13/25 who remained on medical therapy alone.

97 ascular thrombectomy plus medical therapy vs medical therapy alone; time to treatment.

98 ssociated with improved survival relative to medical therapy among patients aged 50 years or older wi

99 outcomes of revascularization compared with medical therapy among patients suitable for CABG.

100 drug use, such as the advent of intravenous medical therapies and devices, and growth in the heroin

101 significant mortality benefit compared with medical therapy and a similar benefit compared with surg

102 cuss the mechanisms by which CSCs may resist medical therapy and contribute to tumor relapse.

103 he authors sought to evaluate trends in both medical therapy and lifestyle counseling for PAD patient

104 history of atrial fibrillation refractory to medical therapy and lung cancer status after left upper

105 ival between an initial strategy of PCI plus medical therapy and medical therapy alone in patients wi

106 rsisted despite at least 3 months of optimal medical therapy and no evidence of cancer recurrence.

107 ocedure (right heart catheterization) versus medical therapy and PFO closure with the Amplatzer PFO O

108 sus 21 [11.2%], respectively; P=0.3) between medical therapy and revascularization, whereas a strong

109 These patients require extensive medical therapy and some develop treatment-resistant dis

110 require reassessment given advances in both medical therapy and surgical techniques.

111 scar reduces the likelihood of a response to medical therapy and to cardiac resynchronization therapy

112 can be useful for designing drug delivery in medical therapy and understanding complicated mechanotra

113 All patients also received standard medical therapy and were followed for 12 months.

114 disorders will require long-term to lifelong medical therapy and/or surveillance.

115 Treatments include transsphenoidal surgery, medical therapies, and radiotherapy.

116 ng as a radiologic biomarker for response to medical therapy, and identifying a variety of disease-re

117 ion and treatment, initiate conservative and medical therapy, and refer to specialists when underlyin

118 Patients may be unreceptive to medical therapy, and some may discontinue the treatment

119 What medical therapies are associated with greatest efficacy

120 devastating sarcomas for which no effective medical therapies are available.

121 Adjuvant medical therapies are designed to prevent recurrences af

122 Effective medical therapies are lacking for the treatment of neuro

123 egression identified compliance with optimal medical therapy as a more powerful predictor of major ad

124 grafting (CABG) added to guideline-directed medical therapy, as compared with medical therapy alone,

125 n strategies were compared: (a) an intensive medical therapy-based management strategy versus (b) an

126 erson and lifetime QALYs were lowest for the medical therapy-based strategy ($14 597, 9.848 QALYs), f

127 The medical therapy-based strategy had a lower life expectan

128 he MR imaging IPH strategy compared with the medical therapy-based strategy was $16 000 per QALY by u

129 for the CVR-based strategy compared with the medical therapy-based strategy was $23 000 per QALY and

130 tensive agents plus lifestyle modification), medical therapy-based treatment with revascularization o

131 10% and normalized (>50%) on evidence-based medical therapies (baseline echocardiogram).

132 recommend prescription of guideline-directed medical therapy before hospital discharge; some of these

133 py is generally transsphenoidal surgery with medical therapy being reserved for those not cured by su

134 randomised, controlled study comparing best medical therapy (BMT, n=116) and bilateral deep brain st

135 and lower utilization of guideline-directed medical therapy but fewer comorbidities and lower B-type

136 remained relatively mild after the start of medical therapy, but 2 patients developed treatment-resi

137 were randomly assigned to undergo CABG plus medical therapy (CABG group, 610 patients) or medical th

138 nd coronary artery disease were allocated to medical therapy, CABG plus medical therapy, or CABG with

139 e is considerable evidence that adherence to medical therapy can affect the outcomes of therapeutic i

140 Despite this, there are no medical therapies capable of modifying disease progressi

141 o have recurrent atrial fibrillation despite medical therapy, catheter ablation has been shown to sub

142 r treatment with endovascular thrombectomy + medical therapy compared with medical therapy alone was

143 Recent clinical trials of new medical therapies continue to inform the care of patient

144 ntation to provide VNS (active) or continued medical therapy (control) in a 3:2 ratio.

145 trial design and comparison of the ICD with medical therapy (control) in at least 100 patients with

146 ma patients with stable IOP and no change in medical therapy during follow-up.

147 significantly between revascularization and medical therapy, either in the CABG stratum (26.1% vs. 2

148 e study of patients with CRS in whom initial medical therapy failed who then self-selected continued

149 Appropriate use of medical therapies for chronic sinusitis is necessary to

150 provided numerous opportunities to transform medical therapies for the treatment of diseases includin

151 tional angiograms before and after intensive medical therapy for 12 months.

152 ngal keratitis not responding to appropriate medical therapy for a period of 2 weeks were randomized

153 has not been shown for patients followed on medical therapy for advanced HF at centers that also off

154 cornerstone of treatment is guideline-driven medical therapy for all patients and implantable device

155 ifiable treatment alternative to surgery and medical therapy for APA.

156 Currently, there is no non-invasive medical therapy for CAVD.

157 underwent either percutaneous PFO closure or medical therapy for comparative analysis.

158 ating with the biliary tree and short-course medical therapy for disseminated disease.

159 smoking, and greater utilization of optimal medical therapy for prevention and treatment of CAD.

160 eceptor (MR) antagonists are the recommended medical therapy for primary aldosteronism.

161 omes for renal artery revascularisation with medical therapy for renal artery stenosis associated wit

162 PFO closure seems as effective as medical therapy for secondary prevention of cryptogenic

163 Guideline-directed medical therapy (GDMT) for heart failure with reduced ej

164 Despite increased use of guideline-directed medical therapy (GDMT), some patients with heart failure

165 D) should be managed with guideline-directed medical therapy (GDMT), which reduces progression of ath

166 ar group and 3.6 (95% CI, 3.5 to 3.8) in the medical therapy group.

167 versus 6 [3.2], P=0.059) was observed in the medical therapy group.

168 (25%) in the PCI group and 277 (24%) in the medical-therapy group (adjusted hazard ratio, 1.03; 95%

169 ABG group and in 398 patients (66.1%) in the medical-therapy group (hazard ratio with CABG vs. medica

170 PFO closure group and in 23 patients in the medical-therapy group (hazard ratio, 0.38; 95% CI, 0.18

171 ABG group and in 524 patients (87.0%) in the medical-therapy group (hazard ratio, 0.72; 95% CI, 0.64

172 %) in the surgery group and in 4 (7%) in the medical-therapy group (P<0.001).

173 e CABG group and 297 patients (49.3%) in the medical-therapy group died from cardiovascular causes (h

174 The patients in the medical-therapy group were assigned to a waiting list fo

175 ups were superior to the changes seen in the medical-therapy group with respect to body weight (-23%,

176 t strategy of optimal medical therapy alone (medical-therapy group) or optimal medical therapy plus P

177 closure group vs. 2669 patient-years in the medical-therapy group), owing to a higher dropout rate i

178 combined with extended-release dipyridamole; medical-therapy group).

179 tients) or to receive medical therapy alone (medical-therapy group, 59 patients).

180 oup, 610 patients) or medical therapy alone (medical-therapy group, 602 patients).

181 PFO closure group and in 28 patients in the medical-therapy group, resulting in rates of 0.58 events

182 roup), owing to a higher dropout rate in the medical-therapy group.

183 common in the PFO closure group than in the medical-therapy group.

184 the gastric-bypass, sleeve-gastrectomy, and medical-therapy groups, respectively), triglyceride leve

185 scular Society II-IV angina, despite optimal medical therapy, >/=1 myocardial segment with inducible

186 scular Society II-IV angina, despite optimal medical therapy, >/=1 myocardial segment with inducible

187 , the declining rate of stroke with improved medical therapy has led to the launch of new clinical tr

188 However, LEF-LG patients assigned to medical therapy have a dismal prognosis independent of M

189 there have been only 5 randomized studies of medical therapies in HCM.

190 This study compared extremes of response to medical therapy in 866 HF patients using a genome-wide a

191 UCS and AMT, as an adjuvant to standard medical therapy in acute chemical injury, are equally ef

192 n renal dysfunction to a greater extent than medical therapy in certain AHF populations.

193 ial of renal artery revascularisation versus medical therapy in heart failure, and suggest that inves

194 terectomy, and can be clinically improved by medical therapy in inoperable patients.

195 tireflux surgery may prevent EAC better than medical therapy in patients with Barrett's esophagus.

196 ndomized trials comparing PFO closure versus medical therapy in patients with cryptogenic stroke.

197 MBS is superior to medical therapy in reducing hyperglycemia in persons wit

198 of coronary revascularization compared with medical therapy in the BARI-2D (Bypass Angioplasty Revas

199 were lower after revascularization than with medical therapy in the CABG stratum (15.3% vs. 30.3%, p

200 f hypercortisolism) is adenoma resection and medical therapies including ketoconazole, mifepristone,

201 s of acute ischemic stroke to receive either medical therapy (including intravenous alteplase when el

202 h of symptom onset were randomly assigned to medical therapy (including intravenous alteplase when el

203 No effective medical therapy is available for the treatment of such p

204 AMI and acute heart failure or shock in whom medical therapy is failing.

205 ltiple RFs through protocol-guided intensive medical therapy is feasible and relates to cardiovascula

206 (RF) goals through protocol-guided intensive medical therapy is feasible or improves outcomes in type

207 Optimal medical therapy is of recognized public health benefit.

208 ormal muscle contractions for which standard medical therapy is often inadequate.

209 Medical therapy is targeted to the anatomical location o

210 Whenever syncope occurs despite optimal medical therapy, LCSD could be considered the next step

211 In 5 of 7 RCTs, PTRAS and medical therapy led to similar BP control in patients wi

212 -LG patients with >/=moderate MR assigned to medical therapy, LEF-LG patients with >/=moderate MR und

213 me of ICU discharge including limitations of medical therapy (LOMT) orders, the time of discharge was

214 ontrolled glaucoma despite maximum tolerated medical therapy, many of whom had failed or were at high

215 Therefore, patient compliance with medical therapy may inform clinical decision making and

216 clerotic disease (ICAD) evolves with current medical therapy may inform secondary stroke prevention.

217 Whether the efficacy of CABG compared with medical therapy (MED) in patients with heart failure cau

218 (PCI) does not improve outcome compared with medical therapy (MT) in patients with stable coronary ar

219 Groups 1, 2, and 3 received UCS with medical therapy (MT), AMT with MT, and MT alone, respect

220 into 2 groups that underwent either AMT with medical therapy (MT; n = 25) or standard MT alone (n = 2

221 ver a limited time horizon on top of maximal medical therapy must be acknowledged before rendering ju

222 ts with major cardiac events despite optimal medical therapy (n=38) was reduced from 100% to 32% (P<0

223 l 1287 patients (endovascular thrombectomy + medical therapy [n = 634]; medical therapy alone [n = 65

224 risk of serious infections due to available medical therapies of inflammatory bowel disease (IBD) re

225 xamines the current state-of-the-art optimal medical therapy (OMT) for patients with known coronary a

226 tinued dual antiplatelet therapy and optimal medical therapy (OMT) improve outcomes in selected patie

227 e is a paucity of data on the use of optimal medical therapy (OMT) in patients with complex coronary

228 apnea were randomized to ASV plus optimized medical therapy (OMT) or OMT alone (control).

229 myocardial infarction compared with optimal medical therapy (OMT), but many patients think otherwise

230 This study determined the effect of optimal medical therapy (OMT), with or without percutaneous coro

231 erm influence of compliance with recommended medical therapy on the comparative outcomes of CABG vers

232 WL) to explore potential impact of effective medical therapy on WL registration.

233 I scores increased postbaseline for CABG and medical therapy only and after 6 months for PCI patients

234 frailty reduction, whereas those assigned to medical therapy only showed stable frailty over the 30-m

235 percutaneous coronary intervention [PCI], 96 medical therapy only) were observed for 30 months.

236 e 0.170, 0.154, and 0.154 for CABG, PCI, and medical therapy only, respectively.

237 Patients in the medical therapy-only group could undergo carotid endarte

238 ication may be permanent and require chronic medical therapy or glaucoma surgery.

239 randomized to Roux-en-Y gastric bypass plus medical therapy or medical therapy alone.

240 omly assigned to atorvastatin-based standard medical therapy or standard therapy plus STS injection (

241 were allocated to medical therapy, CABG plus medical therapy, or CABG with surgical ventricular recon

242 ulmonary artery pressures were used to guide medical therapy, or to the control group, in which daily

243 ng comparable patients who adhere to optimal medical therapy, outcomes of PCI and CABG may not differ

244 patients or surrogate decision makers to use medical therapies over a defined period of time to see i

245 outcomes in patients nonadherent to optimal medical therapy (P=0.001) but were not different in pati

246 ot different in patients adherent to optimal medical therapy (P=0.574).

247 Among medical therapy patients, a significant step-up increase

248 nce imaging, X-ray computer tomography), and medical therapies (photochemothermal therapies, immunoth

249 Medical therapy plays a significant role in optimizing c

250 2014, 206 patients were randomly assigned to medical therapy plus endovascular treatment (n=103) or m

251 apy alone (medical-therapy group) or optimal medical therapy plus PCI (PCI group) and did not find a

252 intensive medical therapy alone or intensive medical therapy plus Roux-en-Y gastric bypass or sleeve

253 should focus both on financial hardship and medical therapy prioritization, particularly in certain

254 Poor metabolic control despite maximal medical therapy prompted two patients to undergo bariatr

255 epatic venous pressure gradient (HVPG)-based medical therapy prophylaxis.

256 Multifaceted medical therapy reduces the risk of stroke in patients w

257 Intensive medical therapy refers to the contemporary approach of a

258 inants of heart failure (HF) and response to medical therapy remain unknown.

259 ention, coronary artery bypass grafting, and medical therapy, respectively (P<0.0001).

260 FFR-driven change in management strategy (medical therapy, revascularization, or additional stress

261 .41-0.86), and islet cell transplantation vs medical therapy (RR 0.25; 95% CI 0.08-0.71).

262 t is not adequately controlled with standard medical therapy should be referred for consideration of

263 In theory, specific medical therapy should halt aortic stenosis progression,

264 y demonstrates that on the basis of standard medical therapy, STS further reduce elevated hs-CRP and

265 ing cause of epilepsy along with appropriate medical therapy (surgery group, 57 patients) or to recei

266 who underwent CABG in addition to receiving medical therapy than among those who received medical th

267 Medical therapies that reduce sebum excretion result in

268 major cause of morbidity and mortality, and medical therapies to treat them are limited.

269 Medical therapy to eliminate thrombus formation in the L

270 ood pressure, may be a target for adjunctive medical therapy to improve outcomes after TAVR.

271 include an exercise program, guideline-based medical therapy to lower the cardiovascular risk, and, w

272 There is no cure and no approved medical therapy to slow or reverse RP.

273 532s; Carl Zeiss Meditec, Jena, Germany) or medical therapy (Travoprost 0.004%; Alcon-Couvreur, Puur

274 s closure of patent foramen ovale (PFO) plus medical therapy versus medical therapy alone for cryptog

275 ndary outcome measures include IOP, glaucoma medical therapy, visual acuity, visual fields, and surgi

276 Endovascular thrombectomy plus medical therapy vs medical therapy alone; time to treatm

277 in revascularisation compared with receiving medical therapy was 0.8 (0.5-1.1, p=0.16).

278 bility of success at 3 years with or without medical therapy was 87% in the Baerveldt group and 76% i

279 Antifungal medical therapy was continued in both groups.

280 espectively, whereas no patient submitted to medical therapy was free of antihypertensive drugs at 12

281 4 of 316 [80.4%]) occurred before 2002, when medical therapy was less intensive; the frequency decrea

282 f 27 to 43, bariatric surgery plus intensive medical therapy was more effective than intensive medica

283 thyroidectomy, alone or in combination with medical therapy, was associated with a 74% decreased haz

284 y rates associated with elective surgery and medical therapy were 34 and 54 deaths per 1000 person-ye

285 storm and cardiogenic shock despite optimal medical therapy were implanted with an extracorporeal li

286 Current medical therapies, which primarily consist of glucocorti

287 Randomized controlled trials comparing IBD medical therapies with no restrictions on language, coun

288 istics over 1 year in subjects randomized to medical therapy with a sham procedure (right heart cathe

289 for symptomatic patients with obstruction is medical therapy with beta-blockers and calcium antagonis

290 ation, and failure as inadequate response to medical therapy with increasing infiltrate size, corneal

291 comparing renal artery stent placement plus medical therapy with medical therapy alone have not show

292 Medical therapy with somatostatin analogues, cabergoline

293 m randomized, controlled trials that compare medical therapy with surgical therapy in patients with t

294 fast electron diffraction, X-ray science and medical therapy with X-rays and electron beams.

295 ization (carotid endarterectomy) and ongoing medical therapy (with antiplatelet, statin, and antihype

296 or had uncontrolled IOP on maximum-tolerated medical therapy, with medicated IOP >/=20 and </=35 mm H

297 U.K. men, the preferred strategy was optimal medical therapy without catheter-based coronary angiogra

298 patients with uncontrolled glaucoma despite medical therapy, without previous incisional glaucoma su

299 riants of HF that associate with response to medical therapy would elucidate the genetic basis of car

300 of stroke and seizure for which no effective medical therapies yet exist.